News
Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for ...
NeuPath Health Inc. (TSXV:NPTH), ("NeuPath" or the "Company"), owner and operator of a network of clinics delivering category ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback